Elmar Kraus analyst DZ BANK

Currently out of the existing stock ratings of Elmar Kraus, 7 are a BUY (53.85%), 6 are a HOLD (46.15%).

Elmar Kraus

Work Performance Price Targets & Ratings Chart

Analyst Elmar Kraus, currently employed at DZ BANK, carries an average stock price target met ratio of 73.33% that have a potential upside of 14.76% achieved within 317 days.

Elmar Kraus’s has documented 26 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LLY, Eli Lilly and Company at 21-Feb-2024.

Wall Street Analyst Elmar Kraus

Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for LLY (ELI LILLY AND COMPANY) at 1/21/2022. The price target of $291 was fulfilled within 75 days with a profit of $54.35 (22.97%) receiving and performance score of 3.06.

Average potential price target upside

BIIB Biogen LLY Eli Lilly and Company AZN AstraZeneca PLC ADR GILD Gilead Sciences AMGN Amgen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$269

$80.62 (42.80%)

$292

13 days ago

39/62 (62.9%)

$83.32 (44.87%)

149

Hold

$202

$13.62 (7.23%)

$214

14 days ago

4/16 (25%)

$17.22 (9.32%)

67

Buy

$285

$96.62 (51.29%)

$285

23 days ago

7/30 (23.33%)

$90.88 (46.82%)

255

Hold

$205

$16.62 (8.82%)

$210

24 days ago

24/26 (92.31%)

$9.19 (4.69%)

206

Buy

$292

$103.62 (55.01%)

$311

1 months 8 days ago

3/9 (33.33%)

$92.73 (46.53%)

747

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Elmar Kraus?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?